TITLE

DIGEST

PUB. DATE
March 2004
SOURCE
Chemical Week;3/31/2004, Vol. 166 Issue 11, p43
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents news briefs on the pharmaceutical and fine chemicals industries as of March 31, 2004. Contract awarded to Bachem to manufacture the peptide drug candidate Lcatibant for Jerini, a private startup pharma company; Collaboration of pharma and fine chemicals firm Nicholas Piramal with Vera Laboratories.
ACCESSION #
12712130

 

Related Articles

  • The beginning of the end for EU specialities? Baker, John // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p5 

    This article reports on the effort of Asian producers to acquire assets in Europe as of October 2005. It was said that such efforts were made to gain market access and technology. According to reports, Avecia revealed it has struck a deal to sell its pharmaceutical custom synthesis business in...

  • Eli Lilly Aims to Expand R&D Operations in India.  // GlobalSourcingNOW;5/30/2007, p3 

    The article reports on the plan of pharmaceutical company Eli Lilly and Co. to expand its research and development outsourcing operations in India. Several factors encourage the company to expand its outsourcing operations in India according to Eli Lilly and Co. India chairman Sandeep Gupta,...

  • NPIL wins two CMG contracts. Tong, Alfred // Asian Chemical News;11/29/2004, Vol. 11 Issue 470, p6 

    Reports on a custom-manufacturing (CMG) agreement signed by Nicholas Piramal (NPIL) with U.S. pharmaceutical companies in November 2004. Information on a CMG contract purchased by NPIL from Alpex International; Advantage of the discontinuation of an agreement with Roche to the company.

  • PHARMACEUTICALS & FINE CHEMICALS.  // Chemical Week;3/9/2009, Vol. 171 Issue 7, p25 

    This section offers news briefs concerning the pharmaceutical industry. Minted International has been acquired for around $40 million by Piramal Pharmaceutical, an Indian pharmaceutical company. Research and Markets reported that China is the primary choice for pharmaceutical outsourcing, which...

  • Nicholas Piramal to spin off. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the approval by shareholders of Nicholas Piramal of the spin-off of the glass and bulk drug units.

  • Nicholas Piramal net rises by 23%. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the financial performance of Nicholas Piramal India Ltd. in the fiscal period 1997-98.

  • NPIL launches contract services.  // Pharmaceutical Technology Europe;Aug2003 Supplement, Vol. 15, p12 

    Focuses on Nicholas Piramal India Ltd.'s offering of its facilities to U.S., European and Japanese multinationals to manufacture their products both for the Indian and global market.

  • NPIL sets ambitious growth targets. Jarvis, Lisa // Chemical Market Reporter;4/18/2005, Vol. 267 Issue 16, p32 

    Highlights the growth targets of Mumbai, India-based Nicholas Piramal India Ltd. Company's plan to leverage the "India advantage" of low-cost, high quality manufacturing as well as its own long track record of multinational partnerships and strong stance respecting intellectual property laws;...

  • Swati Piramal. BOSE, DEEPTI KHANNA // Business Today;10/7/2007, Vol. 16 Issue 20, p84 

    The article profiles Swati Piramal, director of Nicholas Piramal Ltd., one of the biggest pharmaceutical companies in India. She is the only woman member on the Scientific Advisory Board of the Prime Minister. It is noted that she played a significant role in the drug maker's transformation. As...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics